Literature DB >> 35684388

Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy.

David M Campkin1,2, Yuna Shimadate3, Barbara Bartholomew4, Paul V Bernhardt5, Robert J Nash4, Jennette A Sakoff2,6, Atsushi Kato3, Michela I Simone1,2.   

Abstract

Tetrachlorinated phthalimide analogues bearing a boron-pinacolate ester group were synthesised via two synthetic routes and evaluated in their glycosidase modulating and anticancer properties, with a view to use them in boron neutron capture therapy (BNCT), a promising radiation type for cancer, as this therapy does little damage to biological tissue. An unexpected decarbonylation/decarboxylation to five 2,3,4,5-tetrachlorobenzamides was observed and confirmed by X-ray crystallography studies, thus, giving access to a family of borylated 2,3,4,5-tetrachlorobenzamides. Biological evaluation showed the benzamide drugs to possess good to weak potencies (74.7-870 μM) in the inhibition of glycosidases, and to have good to moderate selectivity in the inhibition of a panel of 18 glycosidases. Furthermore, in the inhibition of selected glycosidases, there is a core subset of three animal glycosidases, which is always inhibited (rat intestinal maltase α-glucosidase, bovine liver β-glucosidase and β-galactosidase). This could indicate the involvement of the boron atom in the binding. These glycosidases are targeted for the management of diabetes, viral infections (via a broad-spectrum approach) and lysosomal storage disorders. Assays against cancer cell lines revealed potency in growth inhibition for three molecules, and selectivity for one of these molecules, with the growth of the normal cell line MCF10A not being affected by this compound. One of these molecules showed both potency and selectivity; thus, it is a candidate for further study in this area. This paper provides numerous novel aspects, including expedited access to borylated 2,3,4,5-tetrachlorophthalimides and to 2,3,4,5-tetrachlorobenzamides. The latter constitutes a novel family of glycosidase modulating drugs. Furthermore, a greener synthetic access to such structures is described.

Entities:  

Keywords:  benzamide; boron; boron neutron capture therapy; cancer; glycosidase; phthalimide

Mesh:

Substances:

Year:  2022        PMID: 35684388      PMCID: PMC9182199          DOI: 10.3390/molecules27113447

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.927


  58 in total

1.  NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities.

Authors:  Hugo E. Gottlieb; Vadim Kotlyar; Abraham Nudelman
Journal:  J Org Chem       Date:  1997-10-17       Impact factor: 4.354

2.  Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton.

Authors:  S Sou; S Mayumi; H Takahashi; R Yamasaki; S Kadoya; M Sodeoka; Y Hashimoto
Journal:  Bioorg Med Chem Lett       Date:  2000-05-15       Impact factor: 2.823

3.  4-C-Me-DAB and 4-C-Me-LAB - enantiomeric alkyl-branched pyrrolidine iminosugars - are specific and potent α-glucosidase inhibitors; acetone as the sole protecting group.

Authors:  Filipa P da Cruz; Scott Newberry; Sarah F Jenkinson; Mark R Wormald; Terry D Butters; Dominic S Alonzi; Shinpei Nakagawa; Frederic Becq; Caroline Norez; Robert J Nash; Atsushi Kato; George W J Fleet
Journal:  Tetrahedron Lett       Date:  2011-01-12       Impact factor: 2.415

4.  Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.

Authors:  Nina Raben; Tokiko Fukuda; Abigail L Gilbert; Deborah de Jong; Beth L Thurberg; Robert J Mattaliano; Peter Meikle; John J Hopwood; Kunio Nagashima; Kanneboyina Nagaraju; Paul H Plotz
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

5.  Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams.

Authors:  Yoshinobu Nakagawa; Kyonghon Pooh; Toru Kobayashi; Teruyoshi Kageji; Shinichi Uyama; Akira Matsumura; Hiroaki Kumada
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

6.  Synthesis and α-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-β-d-glucopyranosides.

Authors:  Xiaoli Bian; Xiangni Fan; Changhu Ke; Yajun Luan; Guilan Zhao; Aiguo Zeng
Journal:  Bioorg Med Chem       Date:  2013-06-11       Impact factor: 3.641

Review 7.  Boron neutron capture therapy for glioblastoma.

Authors:  Tetsuya Yamamoto; Kei Nakai; Akira Matsumura
Journal:  Cancer Lett       Date:  2008-03-04       Impact factor: 8.679

8.  Structural development of liver X receptor (LXR) antagonists derived from thalidomide-related glucosidase inhibitors.

Authors:  Tomomi Noguchi-Yachide; Hiroyuki Miyachi; Hiroshi Aoyama; Atsushi Aoyama; Makoto Makishima; Yuichi Hashimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  2007-12       Impact factor: 1.645

9.  Synthesis of N-phenylphthalimide derivatives as alpha-glucosidase inhibitors.

Authors:  Wanchai Pluempanupat; Sirichai Adisakwattana; Sirintorn Yibchok-Anun; Warinthorn Chavasiri
Journal:  Arch Pharm Res       Date:  2007-12       Impact factor: 4.946

10.  A Warburg effect targeting vector designed to increase the uptake of compounds by cancer cells demonstrates glucose and hypoxia dependent uptake.

Authors:  Alexandra Glenister; Michela I Simone; Trevor W Hambley
Journal:  PLoS One       Date:  2019-07-15       Impact factor: 3.240

View more
  1 in total

1.  Women in Bioorganic Chemistry.

Authors:  Francesca Cardona; Camilla Parmeggiani; Camilla Matassini
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.